Department of Radiotherapy, The Fourth Affiliated Hospital of China Medical University , Shenyang, People's Republic of China .
DNA Cell Biol. 2014 Oct;33(10):729-38. doi: 10.1089/dna.2013.2253. Epub 2014 Jun 30.
Many existing studies have demonstrated that p16 promoter methylation might be correlated with the clinicopathologic features of colorectal cancer (CRC), but individually published results are inconclusive. This meta-analysis aimed to derive a more precise estimation of the relationships between p16 promoter methylation and the clinicopathologic features of CRC. We searched the CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, and CBM databases from inception through August 1, 2013. Meta-analysis was performed using the STATA 12.0 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under fixed- or random-effects models. Twenty-seven clinical cohort studies were included with a total of 3311 CRC patients. Our meta-analysis results revealed that p16 promoter methylation was associated with pathological characteristics of CRC (tumor, nodes, metastasis stage: OR=1.55, 95% CI: 1.14-2.13, p=0.006; lymph node metastasis: OR=2.40, 95% CI: 1.37-4.19, p=0.002; histologic grade: OR=2.72, 95% CI: 1.63-4.54, p<0.001; Dukes stage: OR=2.06, 95% CI: 1.57-2.71, p=0.002; tumor size: OR=1.99, 95% CI: 1.03-3.85, p=0.041; location: OR=2.49, 95% CI: 1.95-3.18, p<0.001, respectively). Subgroup analysis by ethnicity suggested that there were also significant correlations between p16 gene promoter methylation and pathological characteristics of CRC among both Caucasian and Asian populations (all p<0.05). Our meta-analysis suggests that promoter methylation of the p16 gene may be strongly correlated with the clinicopathologic features of CRC. Thus, p16 gene promoter methylation may be a potential biomarker for CRC.
许多现有的研究已经表明，p16 启动子甲基化可能与结直肠癌（CRC）的临床病理特征相关，但单独发表的结果并不一致。本荟萃分析旨在更准确地评估 p16 启动子甲基化与 CRC 的临床病理特征之间的关系。我们从建库开始至 2013 年 8 月 1 日，在 CISCOM、CINAHL、Web of Science、PubMed、Google Scholar、EBSCO、Cochrane Library 和 CBM 数据库中进行了检索。使用 STATA 12.0 软件进行荟萃分析。采用固定效应或随机效应模型计算比值比（OR）和 95%置信区间（CI）。共有 27 项临床队列研究，共纳入 3311 例 CRC 患者。我们的荟萃分析结果表明，p16 启动子甲基化与 CRC 的病理特征有关（肿瘤、淋巴结、转移分期：OR=1.55，95%CI：1.14-2.13，p=0.006；淋巴结转移：OR=2.40，95%CI：1.37-4.19，p=0.002；组织学分级：OR=2.72，95%CI：1.63-4.54，p<0.001；Dukes 分期：OR=2.06，95%CI：1.57-2.71，p=0.002；肿瘤大小：OR=1.99，95%CI：1.03-3.85，p=0.041；位置：OR=2.49，95%CI：1.95-3.18，p<0.001）。按种族进行的亚组分析表明，p16 基因启动子甲基化与白种人和亚洲人群 CRC 的病理特征之间也存在显著相关性（均 p<0.05）。本荟萃分析表明，p16 基因启动子甲基化与 CRC 的临床病理特征密切相关。因此，p16 基因启动子甲基化可能是 CRC 的一个潜在生物标志物。
